These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26054088)

  • 21. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
    Pham A; Chen R
    Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brentuximab vedotin for Hodgkin lymphoma who had failed allogeneic stem cell transplantation: a multicenter retrospective study.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):12-4. PubMed ID: 25768995
    [No Abstract]   [Full Text] [Related]  

  • 23. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.
    van der Weyden CA; Pileri SA; Feldman AL; Whisstock J; Prince HM
    Blood Cancer J; 2017 Sep; 7(9):e603. PubMed ID: 28885612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.
    Monjanel H; Deville L; Ram-Wolff C; Venon MD; Franchi P; Benet C; de Kerviler E; Malphettes M; Thieblemont C; Brice P
    Br J Haematol; 2014 Jul; 166(2):306-8. PubMed ID: 24673542
    [No Abstract]   [Full Text] [Related]  

  • 25. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.
    Younes A
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):27-32. PubMed ID: 24287065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brentuximab Vedotin (SGN-35).
    Katz J; Janik JE; Younes A
    Clin Cancer Res; 2011 Oct; 17(20):6428-36. PubMed ID: 22003070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brentuximab vedotin in Hodgkin's lymphoma.
    Pro B; Perini GF
    Expert Opin Biol Ther; 2012 Oct; 12(10):1415-21. PubMed ID: 22937794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
    Minich SS
    Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Durable Responses with Brentuximab Vedotin in cHL.
    Cancer Discov; 2016 Sep; 6(9):OF1. PubMed ID: 27507410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
    Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
    Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
    [No Abstract]   [Full Text] [Related]  

  • 31. CD30-positive cutaneous T-cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases.
    Mody K; Wallace JS; Stearns DM; Bowers G; Lacy SR; Levy NB; Zug KA; Lansigan F
    Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):319-23. PubMed ID: 23313068
    [No Abstract]   [Full Text] [Related]  

  • 32. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
    Bhatt G; Maddocks K; Christian B
    Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.
    Nagai H
    Jpn J Clin Oncol; 2015 Feb; 45(2):137-45. PubMed ID: 25489004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
    Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL
    Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-Agent Brentuximab as Bridging Therapy for Hodgkin Lymphoma Patients With Hepatic Impairment.
    Gupta A; Petrasek J; Sen S; Gopal P; Naina HV
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):e11-4. PubMed ID: 26775723
    [No Abstract]   [Full Text] [Related]  

  • 36. Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features.
    Zibara V; Sen F; Scordo M; Falchi L
    Leuk Lymphoma; 2022 Dec; 63(13):3241-3244. PubMed ID: 36120859
    [No Abstract]   [Full Text] [Related]  

  • 37. CD30 as a therapeutic target for lymphoma.
    Schirrmann T; Steinwand M; Wezler X; Ten Haaf A; Tur MK; Barth S
    BioDrugs; 2014 Apr; 28(2):181-209. PubMed ID: 24043362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-time ultrasound elastography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Squillaci E; Antonicoli M; Manenti G; Bolacchi F
    Eur Rev Med Pharmacol Sci; 2016 Apr; 20(8):1628-35. PubMed ID: 27160139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma.
    Dozzo M; Zaja F; Volpetti S; Sperotto A; Magli A; Fanin R
    Am J Hematol; 2015 Apr; 90(4):E73. PubMed ID: 25546725
    [No Abstract]   [Full Text] [Related]  

  • 40. Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure.
    Nathwani N; Krishnan AY; Huang Q; Kim Y; Karanes C; Smith EP; Forman SJ; Sievers E; Thomas SH; Chen RW
    Leuk Lymphoma; 2012 Oct; 53(10):2051-3. PubMed ID: 22369501
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.